Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	6/1/2006 10:02:41 AM
	of 3044

Merrill: MLN1202 hits primary endpoint of reducing CRP MLNM announced positive top-line data from a phase II trial of MLN1202, an anti- CCR2 receptor antibody, in patients at high risk for atherosclerosis. MLN1202 met its primary endpoint of reducing the level of C-Reactive Protein (CRP)(p=0.0275), an inflammatory biomarker associated with cardiovascular disease. Reducing CRP may lower risk of cardiovascular events, but actual clinical benefit from MLN1202 is unclear at this early stage. While the early data is encouraging, the antibody does not fit with Millennium’s strategic focus on oncology and we would not expect the company to commercialize it on its own. Maintain Neutral. Anti-CCR2 antibody may reduce inflammation in arteries The phase II trial enrolled 108 patients with high CRP levels. They received either a single dose of MLN1202 or placebo and were evaluated over a period of months for tolerability and CRP levels. There were no serious adverse events. The CCR2 receptor on white blood cells may play a role in their concentration at sites of inflammation in the arteries, and by antagonizing the receptor, the anti- CCR MLN1202 antibody may help reduce the inflammation, possibly reflected by a reduction in the CRP biomarker. But additional studies will be needed. Oncology remains the company’s focus MLN1202 is also in a phase II trial for the treatment of relapsing-remitting multiple sclerosis and data are expected in 1H07, but MLNM’s focus is on expanding Velcade’s label and securing additional sources of revenue in the oncology setting. We expect phase II clinical data updates at ASCO for Velcade in mantle cell lymphoma (PINNACLE study, Abstract #7512), in non-small cell lung cancer (SWOG trial, Abstract #7017) and front-line multiple myeloma (Abstract #7504).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next